

EMVision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au

## **ASX** Release

# CLINICAL TRIAL PROGRESSING WELL AND ASA PROJECT MILESTONE ACHIEVED

#### Highlights:

- All three clinical trial sites now enrolling, with Princess Alexandra Hospital, Brisbane now live.
- Enrolment milestone reached under Project Agreement with the Australian Stroke Alliance (ASA) to trigger a further \$600,000 non-dilutive milestone payment.
- Maintaining excellent enrolment rates, exemplifying the non-invasive and user-friendly nature of the EMVision brain scanner, alongside the dedication of our clinical research collaborators.
- A successful outcome from the pre-validation and validation trial phases will demonstrate that EMVision's portable brain scanner can provide crucial insights that enable clinicians to make critical decisions earlier in stroke care, when time matters, at the point-of-care. In addition, it intends to generate the prerequisite data for major market regulatory submissions, including FDA.

**EMVision Medical Devices Limited (ASX:EMV)** ("EMVision" or the "Company") is pleased to advise that all three clinical trial sites are live, with enrolment now open at Princess Alexandra Hospital, Brisbane.

Princess Alexandra Hospital, Brisbane, is part of Metro South Health, a major medical research precinct and comprehensive stroke centre. EMVision has an ongoing clinical expertise, research and innovation collaboration with Metro South Health and the Princess Alexandra Hospital was the clinical site for EMVision's earlier successful 'proof of concept' clinical trial.

EMVision has also achieved the following important milestone under its Project Agreement with the Australian Stroke Alliance (ASA), which is funded by the Commonwealth of Australia's Medical Research Future Fund (MRFF), "Algorithm validation study - patient enrolment commenced". EMVision has submitted the required documentation to the ASA to trigger a further \$600,000 non-dilutive milestone payment.

EMVision CEO & MD, Scott Kirkland said, "Our vision is to drive innovation in end-to-end stroke management, at the point-of-care, wherever the patient is. Our technology has the potential to enable earlier diagnosis in the acute phase and aid bedside post-treatment and intervention monitoring in a manner otherwise not possible today. We're making good progress in our study, amassing critical data from both 'front door' and follow up scans and we look forward to continuing accelerated enrolment into the study and reporting to the market of its progress".

Authorised for release by the Board of the Company.


### [ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys Investor Relations +61 400 400 800 andrew.keys@keysthomas.com Sling & Stone Media and Communications emvision@slingstone.com 02 8073 5390 Scott Kirkland CEO and Managing Director +61 2 8667 5337 skirkland@emvision.com.au

#### **Clinical Investigations Roadmap**

The sites have been activated progressively, commencing with Liverpool Hospital. All sites that have been selected are major stroke centres that treat significant volumes of stroke patients each year.



#### **About EMVision Medical Devices**

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

#### **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeayour of building a business around such products and services. These statements are not quarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

#### Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.